AR107828A1 - 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k - Google Patents
2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3kInfo
- Publication number
- AR107828A1 AR107828A1 ARP170100571A ARP170100571A AR107828A1 AR 107828 A1 AR107828 A1 AR 107828A1 AR P170100571 A ARP170100571 A AR P170100571A AR P170100571 A ARP170100571 A AR P170100571A AR 107828 A1 AR107828 A1 AR 107828A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihydroimidazo
- compounds
- carboxamids
- metoxi
- quinazolin
- Prior art date
Links
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 abstract 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NTTQCLSBWRKUIJ-UHFFFAOYSA-N 2,3-dihydroimidazo[1,2-c]quinazoline Chemical class C1=CC=C2C3=NCCN3C=NC2=C1 NTTQCLSBWRKUIJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos de 2,3-dihidroimidazo[1,2-c]quinazolina, composiciones farmacéuticas que contienen dichos compuestos y al uso de dichos compuestos o composiciones para la inhibición de fosfatidilinositol-3-quinasa (PI3K) y para el tratamiento de enfermedades asociadas con la actividad de fosfatidilinositol-3-quinasa (PI3K), en particular para el tratamiento de trastorno hiperproliferativos y/o angiogénicos, como único agente o en combinación con otros ingredientes activos. Reivindicación 1: Un compuesto de fórmula general (1), caracterizado porque: R¹ representa un átomo de hidrógeno o un grupo -C(=O)H; y R¹ representa un grupo -(CH₂)₂OH; o: R¹ y R¹, junto con el átomo de N al cual están unidos, forman un grupo morfolinilo el cual es sustituido con 1 ó 2 sustituyentes seleccionados independientemente entre -OH y =O; o una sal, solvato, hidrato o estereoisómero fisiológicamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16159156 | 2016-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107828A1 true AR107828A1 (es) | 2018-06-13 |
Family
ID=55521577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100571A AR107828A1 (es) | 2016-03-08 | 2017-03-08 | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10844066B2 (es) |
| EP (1) | EP3426657B1 (es) |
| JP (1) | JP6935415B2 (es) |
| CN (1) | CN108884098B (es) |
| AR (1) | AR107828A1 (es) |
| CA (1) | CA3016584A1 (es) |
| TW (1) | TW201736375A (es) |
| UY (1) | UY37149A (es) |
| WO (1) | WO2017153220A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
| EP3645005A1 (en) | 2017-06-28 | 2020-05-06 | Bayer Consumer Care AG | Combination of a pi3k-inhibitor with an androgen receptor antagonist |
| FR3072024A1 (fr) * | 2017-10-11 | 2019-04-12 | Olivier Petitjean | Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale |
| KR102618168B1 (ko) * | 2018-07-06 | 2023-12-27 | 일양약품주식회사 | 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물 |
| CN109674817B (zh) * | 2019-01-31 | 2021-06-29 | 哈尔滨医科大学 | 三氧化二砷在制备治疗晚期动脉粥样硬化药物中的用途 |
| CN110656152A (zh) * | 2019-10-11 | 2020-01-07 | 郑州大学 | 一种艾曲波帕介导巨噬细胞抗血管生成作用验证方法 |
| CN114223613B (zh) * | 2021-11-30 | 2023-03-21 | 西安医学院 | 一种基于aav8-pcsk9诱导的高胆固醇血症和动脉粥样硬化小鼠模型及构建方法 |
| AU2024306046A1 (en) * | 2023-06-26 | 2026-01-22 | Athos Therapeutics, Inc. | Small molecules for the treatment of autoimmune disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131159B1 (hr) | 2002-09-30 | 2019-11-01 | Bayer Ip Gmbh | Taljeni azol-pirimidin derivati |
| AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009091550A2 (en) | 2008-01-14 | 2009-07-23 | Bayer Healthcare Llc | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
| EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| CA2796253A1 (en) | 2010-04-16 | 2011-10-20 | Bayer Intellectual Property Gmbh | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
| JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| UA119537C2 (uk) | 2013-04-08 | 2019-07-10 | Байєр Фарма Акцієнгезелльшафт | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ |
| EP3077002B1 (en) | 2013-12-03 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
| EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
| KR20180013850A (ko) | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 |
| CN107864625B (zh) | 2015-03-09 | 2021-05-28 | 拜耳制药股份公司 | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 |
| BR112018015782A2 (pt) | 2016-02-01 | 2019-01-02 | Bayer Pharma AG | biomarcadores de copanlisibe |
| JP2019512003A (ja) | 2016-02-01 | 2019-05-09 | バイエル ファーマ アクチエンゲゼルシャフト | コパンリシブバイオマーカー |
| CN109729716B (zh) | 2016-09-23 | 2022-03-15 | 拜耳制药股份公司 | Pi3k-抑制剂的组合产品 |
-
2017
- 2017-03-01 CA CA3016584A patent/CA3016584A1/en active Pending
- 2017-03-01 US US16/082,712 patent/US10844066B2/en not_active Expired - Fee Related
- 2017-03-01 CN CN201780015935.9A patent/CN108884098B/zh not_active Expired - Fee Related
- 2017-03-01 JP JP2018546820A patent/JP6935415B2/ja not_active Expired - Fee Related
- 2017-03-01 EP EP17707070.3A patent/EP3426657B1/en active Active
- 2017-03-01 WO PCT/EP2017/054736 patent/WO2017153220A1/en not_active Ceased
- 2017-03-07 TW TW106107337A patent/TW201736375A/zh unknown
- 2017-03-08 AR ARP170100571A patent/AR107828A1/es unknown
- 2017-03-08 UY UY0001037149A patent/UY37149A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019507770A (ja) | 2019-03-22 |
| US20190092775A1 (en) | 2019-03-28 |
| CN108884098A (zh) | 2018-11-23 |
| CA3016584A1 (en) | 2017-09-14 |
| JP6935415B2 (ja) | 2021-09-15 |
| UY37149A (es) | 2017-10-31 |
| TW201736375A (zh) | 2017-10-16 |
| WO2017153220A1 (en) | 2017-09-14 |
| EP3426657B1 (en) | 2022-07-13 |
| EP3426657A1 (en) | 2019-01-16 |
| US10844066B2 (en) | 2020-11-24 |
| CN108884098B (zh) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| JOP20220069A1 (ar) | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| AR105808A1 (es) | Compuestos de amida para el tratamiento de trastornos médicos | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| UY36207A (es) | Inhibidores de la syk | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| BR112015023412A8 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso. | |
| UY35586A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| ECSP13012618A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| AR119479A1 (es) | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112017010439A2 (pt) | composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |